Janssen Pharmaceutica Nv

Ortho-mcneil Pharmaceutical Corp.

Cailin Chen

Bruce E Maryanoff

Han-Cheng Zhang

Hong Ye

Andrew Lawrence Darrow

Patricia Andrade-Gordon

Jian-Shen Qi

Kimberly White

Stephen C Yabut

The present invention is directed to novel 2,3-dihydro-1H-isoindol-1-imine derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the thrombin PAR-1 receptor antagonists.

2,3-dihydro-1H-isoindol-1-imine derivatives useful as thrombin PAR-1 receptor antagonist

The present invention is directed to novel bicyclic triazolopyrimidine compounds of Formula (I) or a form thereof: wherein X, X, R, R, Rand Rare as defined herein, and their methods of preparation and use as ADP inhibitors.

[object Object]

The present invention is directed to novel bicyclic triazolopyrimidine compounds of Formula (I) or a form thereof: wherein Rand Rare as defined herein, and their methods of preparation and use as ADP inhibitors.

A novel human cDNA, termed PRSS11-L, was isolated which encodes a polypeptide that belongs to the S2/HtrA serine protease family. The PRSS11-L mRNA is widely expressed in several tissues throughout the body by multi-tissue Northern blotting. The full-length PRSS11-L cDNA, was cloned, expressed and purified. Proteolytic activity was demonstrated using the protein substrate casein. The isolated nucleic acid or polypeptide molecule of the invention can be used in detection assays, gene therapy, and screening assays.

Human PRSS11-like S2 serine protease and uses thereof

A novel human nucleic acid and polypeptide, termed PRSS11-L, are disclosed. PRSS11-L, which is observed in tissues throughout the body, can be used in methods of detection, gene therapy, and screening.

Growing community of inventors

New Hope, PA, United States of America

Cailin Chen